The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An investigation into vaccinating against mutated RAS in multiple myeloma
RAS mutations are the most common genetic aberrations observed in multiple myeloma (MM). In this video, Hanne Norseth, MD, Oslo University Hospital, Oslo, Norway, introduces the Phase I TG01 study (NCT05841550), which assesses the use of vaccination against mutated RAS in patients with myeloma. Patients enrolled in the trial have either high-risk smoldering myeloma (HR-SMM) or stable/indolent disease, meaning the effect of the vaccine can be studied. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoria: Janssen, BM; Advisory board: Sanofi; Researh funding: Circio.
